Global Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Pre-Mixed, Inhaled, Ultra-Long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By Region, Forecast & Opportunities, 2025New York, Jan. 04, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Human Insulin Market, By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025” – https://www.reportlinker.com/p05916737/?utm_source=GNW Global human insulin market was valued at USD 26.91 Billion in 2019 is expected to grow at a steady CAGR of 8.01% during the forecast period. Growing geriatric population, increasing diabetic patients, rising prevalence of obesity, and increasing demand for human insulin analogs are contributing to the surging demand for human insulin market, globally. Now a days, diabetes is not only restricted to geriatric population, but it is also common among youth. Also, the technological advancements have eradicated human physical activities leading to obesity and diabetes disorders which is directly influencing the growth of the market. Cost effectiveness, reimbursement prices and strict regulatory requirements for approval of insulin can be considered as a major restraining factor for the market as everyone suffering from diabetes might not be able to afford insulin. The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products, and region.Based on indication, market can be bifurcated into type I diabetes and type II diabetes. Type I diabetes is likely to hold the largest market share until 2025 as, human insulin is the most important treatment method for the people suffering from type I diabetes. Based on brand, Lantus segment held the dominant market which is one of the major selling products of Sanofi S.A. As of 2019, subcutaneous segment was the leading segment on the basis of route of administration. This is the most common and preferred route of administration as the insulin is absorbed more quickly. Based on regional analysis, North America dominated the human insulin market in 2019 due to large pool of population suffering from diabetes and presence of leading companies in countries like US and Canada. Leading players in the global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk A/S, Torrent Pharmaceuticals, Inc., Eli Lilly and Company, A-S Medication Solutions, RemedyRepack Inc., Sedico Co., Pharmaceutical Company, Sanofi S.A., Gan & Lee Pharmaceuticals, BioGenomics Ltd., Pfizer Inc., PerkinElmer, Merck & Co., Inc, Biocon Limited, Wockhardt Ltd., Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., among others. Years considered for this report: Historical Years: 2015-2018 Base Year: 2019 Estimated Year: 2020 Forecast Period: 2021–2025 Objective of the Study: • To analyze and forecast the market size of global human insulin market. • To classify and forecast global human insulin market based on indication, brand, route of administration, type, onset type, products and region. • To identify drivers and challenges for global human insulin market. • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global human insulin market. • To conduct pricing analysis for global human insulin market. • To identify and analyze the profile of leading players operating in global human insulin market. The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of hospitals/clinics across the globe. Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors. Through this technique, the analyst could include the hospitals/clinics which could not be identified due to the limitations of secondary research. The analyst examined the hospitals/clinics and presence of all major players across the globe. The analyst calculated the market size of global human insulin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst. Key Target Audience: • Hospitals/clinics, research institutes and other stakeholders • Government bodies such as regulating authorities and policy makers • Organizations, forums and alliances related to human insulin • Market research and consulting firms The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals/clinics, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities. Report Scope: In this report, global human insulin market has been segmented into following categories, in addition to the industry trends which have also been detailed below: • Market, By Indication: o Type I Diabetes o Type II Diabetes • Market, By Brand: o Lantus o Humulin R o Novolin R o Humulin N o Exubera o Afrezza o Novolin N • Market, By Route of Administration: o Subcutaneous o Nasal o Intravenous o Transdermal o Oral o Others • Market, By Type: o Basal o Bolus o Pre-mixed o Biosimilar o Traditional • Market, By Onset Time: o Rapid acting o Short-acting o Intermediate acting o Long acting o Ultra-long acting o Pre-mixed o Inhaled • Market, By Products: o Insulin Pens o Insulin Pumps o Infusion System o Injection • Market, By Region: o North America United States Mexico Canada o Europe Germany United Kingdom France Italy Spain Russia o Asia-Pacific China India Japan South Korea Australia Singapore o South America Brazil Argentina Colombia o Middle east & Africa Saudi Arabia South Africa UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in global human insulin market. Available Customizations: With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report: Company Information • Detailed analysis and profiling of additional market players (up to five). Read the full report: https://www.reportlinker.com/p05916737/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place. __________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
NEW YORK (AP) — Shares of Tesla soared Wednesday as investors bet that the electric vehicle maker and its CEO Elon Musk will benefit from Donald Trump’s return to the White House.
Tesla stands to make significant gains under a Trump administration with the threat of diminished subsidies for alternative energy and electric vehicles doing the most harm to smaller competitors. Trump’s plans for extensive tariffs on Chinese imports make it less likely that Chinese EVs will be sold in bulk in the U.S. anytime soon.
“Tesla has the scale and scope that is unmatched,” said Wedbush analyst Dan Ives, in a note to investors. “This dynamic could give Musk and Tesla a clear competitive advantage in a non-EV subsidy environment, coupled by likely higher China tariffs that would continue to push away cheaper Chinese EV players.”
Tesla shares jumped 14.8% Wednesday while shares of rival electric vehicle makers tumbled. Nio, based in Shanghai, fell 5.3%. Shares of electric truck maker Rivian dropped 8.3% and Lucid Group fell 5.3%.
Tesla dominates sales of electric vehicles in the U.S, with 48.9% in market share through the middle of 2024, according to the U.S. Energy Information Administration.
Subsidies for clean energy are part of the Inflation Reduction Act, signed into law by President Joe Biden in 2022. It included tax credits for manufacturing, along with tax credits for consumers of electric vehicles.
Musk was one of Trump’s biggest donors, spending at least $119 million mobilizing Trump’s supporters to back the Republican nominee. He also pledged to give away $1 million a day to voters signing a petition for his political action committee.
In some ways, it has been a rocky year for Tesla, with sales and profit declining through the first half of the year. Profit did rise 17.3% in the third quarter.
The U.S. opened an investigation into the company’s “Full Self-Driving” system after reports of crashes in low-visibility conditions, including one that killed a pedestrian. The investigation covers roughly 2.4 million Teslas from the 2016 through 2024 model years.
And investors sent company shares tumbling last month after Tesla unveiled its long-awaited robotaxi at a Hollywood studio Thursday night, seeing not much progress at Tesla on autonomous vehicles while other companies have been making notable progress.
TORONTO – Canada’s main stock index was up more than 100 points in late-morning trading, helped by strength in base metal and utility stocks, while U.S. stock markets were mixed.
The S&P/TSX composite index was up 103.40 points at 24,542.48.
In New York, the Dow Jones industrial average was up 192.31 points at 42,932.73. The S&P 500 index was up 7.14 points at 5,822.40, while the Nasdaq composite was down 9.03 points at 18,306.56.
The Canadian dollar traded for 72.61 cents US compared with 72.44 cents US on Tuesday.
The November crude oil contract was down 71 cents at US$69.87 per barrel and the November natural gas contract was down eight cents at US$2.42 per mmBTU.
The December gold contract was up US$7.20 at US$2,686.10 an ounce and the December copper contract was up a penny at US$4.35 a pound.
This report by The Canadian Press was first published Oct. 16, 2024.
TORONTO – Canada’s main stock index was up more than 200 points in late-morning trading, while U.S. stock markets were also headed higher.
The S&P/TSX composite index was up 205.86 points at 24,508.12.
In New York, the Dow Jones industrial average was up 336.62 points at 42,790.74. The S&P 500 index was up 34.19 points at 5,814.24, while the Nasdaq composite was up 60.27 points at 18.342.32.
The Canadian dollar traded for 72.61 cents US compared with 72.71 cents US on Thursday.
The November crude oil contract was down 15 cents at US$75.70 per barrel and the November natural gas contract was down two cents at US$2.65 per mmBTU.
The December gold contract was down US$29.60 at US$2,668.90 an ounce and the December copper contract was up four cents at US$4.47 a pound.
This report by The Canadian Press was first published Oct. 11, 2024.
